3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, commonly known as statins, are the medical treatment of choice for hypercholesterolemia. In addition to achieving a therapeutic decrease in serum cholesterol levels, statin therapy appears to promote pleiotropic effects that are independent of changes in serum cholesterol. These cholesterol lowering and pleiotropic effects are beneficial not only for the coronary circulation, but for the myocardium and peripheral arterial system as well. Patients receiving statin therapy must be carefully monitored, however, as statins potentially have harmful side effects and drug interactions. This article is part II of a 2-part review, and it focuses on the clinical aspects of statin therapy in cardiovascular disease.
Endo A., Kuroda M., Tsujita Y.ML-236A, ML-236B, ML-236C, new inhibitors of cholesterolgenesis produced by. Penicillium citrinium. J Antibiot (Tokyo). 1976;29(12):1346-1348.
2.
Liao JK, Laufs U.Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol . 2005;45:89-118.
3.
Alberts AW, Chen J., Kuron G., et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci. 1980;77(7):3957-3961.
4.
Alberts AWLovastatin and simvastatin-inhibitors of HMGCoA reductase and cholesterol biosynthesis. Cardiology. 1990; 77(suppl 4):14-21.
5.
Tobert JALovastatin and beyond: the history of the HMG-CoA reductase inhibitors . Nature. 2003;2(7):517-526.
6.
Sytkowski PA , Kannel WB, D’Agostino RBChanges in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. N Engl J Med. 1990;322(24): 1635-1641.
7.
Takemoto M., Liao JKPleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors . Arterioscler Thromb Vasc Biol. 2001;21(11):1712-1719.
8.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet. 1994;344(8934):1383-1389.
9.
Heart Protection Study Collaborative group.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
10.
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349-1357.
11.
Downs JR, Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS . JAMA. 1998;279(20):1615-1622.
12.
Sever PS, Dahlof B., Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations , in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149-1158.
13.
Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364(9435):685-696.
14.
Shepherd J. , Cobbe SM, Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia . West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 ;333(20):1301-1307.
15.
Nissen SE, Nicholls SJ, Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556-1565.
16.
Nissen SEHalting the progression of atherosclerosis with intensive lipid lowering: results from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Am J Med. 2005;118(suppl 12A):22S-27S.
17.
Nissen SE, Tuzcu EM, Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial . JAMA. 2004;291(9):1071-1080.
18.
Cannon CP, Braunwald E., McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004 ;350(15):1495-1504.
19.
de Lemos JA , Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004; 292(11):1307-1316.
20.
LaRosa JC , Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-1435.
21.
Pedersen TR , Faergman O., Kastelein JP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. JAMA. 2005;294(19):2437-2445.
22.
Cohn JN, Ferrari R., Sharpe N.Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol . 2000;35(3):569-582.
23.
Kurian KC, Rai P., Sankaran S., Jacob B., Chiong J., Miller ABThe effect of statins in heart failure: beyond its cholesterol-lowering effect . J Card Fail. 2006;12(6):473-478.
24.
Reddy R., Chahoud G., Mehta JLModulation of cardiovascular remodeling with statins: fact or fiction ? Curr Vasc Pharmacol. 2005;3(1):69-79.
25.
Tan LB, Jalil JE, Pick R., Janicki JS, Weber KTCardiac myocyte necrosis induced by angiotensin II. Circ Res . 1991;69(5): 1185-1195.
26.
Olivetti G. , Abbi R., Quaini F., et al. Apoptosis in the failing human heart . N Engl J Med. 1997 ;336(16):1131-1141.
27.
Sadoshima J. , Izumo S.Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts: critical role of the AT1 receptor subtype. Circ Res. 1993;73(3):413-423.
28.
Goodfriend TL, Elliott ME, Catt KJAngiotensin receptors and their antagonists . N Engl J Med. 1996 ;334(25):1649-1654.
29.
Lindpaintner K., Ganten D.The cardiac renin-angiotensin system: an appraisal of present experimental and clinical evidence. Circ Res. 1991;68(4):905-921.
30.
Sarkar S., Vellaichamy E., Young D., Sen S. Influence of cytokines and growth factors in ANG II-mediated collagen upregulation by fibroblasts in rats: role of myocytes. Am J Physiol Heart Circ Physiol. 2004;287(1):107-117.
31.
Lane KT, Beese L.Structural biology of protein farnesylation and geranylgeranyltransferase typeI. J Lipid Res. 2006;47(4): 681-699.
32.
Ichiki T., Takeda K., Tokunou T., et al. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2001;21(12):1896-1901.
33.
Nickenig G. , Baumer AT, Temur Y., Kebben D., Jockenhövel F., Böhm M.Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men . Circulation. 1999;100(21): 2131-2134.
34.
Dechend R., Fiebeler A., Park JK, et al. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Circulation. 2001;104(5):576-581.
35.
Sadek MM, Haddad T., Haddad H.The role of statins in chronic heart failure. Curr Opin Cardiol . 2009;24(2):167-171.
36.
Tousoulis D. , Charakida M., Stefanadi E., Siasos G., Latsios G., Stefanadis C.Statins in heart failure. Beyond the lipid lowering effect. Int J Cardiol . 2007;115(2):144-150.
37.
van der Harst P., Voors AA, van Gilst WH, et al. Statins in the treatment of chronic heart failure: biological and clinical considerations . Cardiovasc Res. 2006;71(3):443-454.
38.
Moosmann B. , Behl C.Selenoprotein synthesis and side-effects of statins. Lancet. 2004;363(9412):892-894.
Kjekshus J. , Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med . 2007 ; 357(22):2248-2261.
41.
Investigators GISSI-HF.Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645): 1231-1239.
42.
Endres M., Laufs U.Discontinuation of statin treatment in stroke patients. Stroke . 2006;37(10):2640-2643.
43.
Centers for Disease Control and Prevention (CDC).Prevalence of disabilities and associated health conditions among adults: United States, 1999. Morb Mortal Wkly Rep.2001;50(7):120-125.
44.
Rosamond W. , Flegal K., Friday G., et al. Heart disease and stroke statistics-2007 update. Circulation. 2007;115(5):e69-e171.
45.
Spence JDStroke prevention in the high-risk patient. Exp Opin Lipidol . 2007;8(12):1851-1859.
46.
Kannel WB, Castelli WP, Gordon T., McNamara PMSerum cholesterol, lipoproteins, and the risk of coronary heart disease . Ann Intern Med. 1971;74(1):1-12.
47.
Multiple risk factor intervention trial.Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA. 1982;248(12):1465-1477.
48.
Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996 ;335(14):1001-1009.
49.
Collins R., Armitage J., Parish S., Sleight P., Peto R.Heart Protection Study Collaborative Group.Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363(9411):757-767.
50.
Kubes P., Suzuki M., Granger DNNitric oxide: an endogenous modulator of leucocyte adhesion. Proc Natl Acad Sci U S A. 1991;88(11):4651-4655.
51.
Radomski MW , Palmer RMJ, Moncada S.Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol. 1987;92(1):181-187.
52.
Dalkara T., Yoshida T., Irikura K., Moskowitz MADual role of nitric oxide in focal cerebral ischemia. Neuropharmacology . 1994;33(11):1447-1452.
53.
Huang Z., Huang PL, Panahian N., Dalkara T., Fishman MC, Moskowitz MAEffects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase . Science. 1994;265(5180): 1883-1885.
54.
Endres M., Laufs U., Gertz K., et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1998;95(15):8880-8885.
55.
Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998;101(12):2711-2719.
56.
Kaesemeyer WH , Caldwell RB, Huang J., Caldwell RWPravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol. 1999;33(1):234-241.
57.
Laufs U., Gertz K., Dirnagl U., Böhm M., Nickenig G., Endres M.Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res. 2002;942(1-2):23-30.
Barnett HJThe pathophysiology of transient cerebral ischemic attacks. Med Clin North Am. 1979;63(4):649-679.
60.
Hollenhorst RWVascular status of patients who have cholesterol emboli in the retina. Am J Ophthalmol. 1966 ;61(5 pt 2): 1159-1165.
61.
Russell RWObservations on the retinal blood-vessels in monocular blindness. Lancet. 1961;2(7218):1422-1428.
62.
del Zoppo GJThe role of platelets in ischemic stroke. Neurology. 1998;51(33):S9-S14.
63.
Mayer J., Eller T., Brauer P., et al. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol. 1992 ;64(4):196-201.
64.
Notarbartolo A., Davi G., Averna M., et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995; 15(2):247-251.
65.
Labios M., Martinez M., Gabriel F., Guiral V., Martínez E., Aznar J.Effect of atorvastatin upon platelet activation in hypercholesterolemia, evaluated by flow cytometry. Thromb Res. 2005 ;115(4): 263-270.
66.
Huhle G., Abletshauser C., Mayer N., Weidinger G., Harenberg J., Heene DLReduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. Thromb Res. 1999;95(5):229-234.
67.
Stuve O., Youssef S., Steinman L., Zamvil SSStatins as potential therapeutic agents in neuroinflammatory disorders . Curr Opin Neurol. 2003;16(3):393-401.
68.
Carr S., Farb A., Pearce WH, Virmani R., Yao JSAtherosclerotic plaque rupture in symptomatic carotid artery stenosis . J Vasc Surg. 1996;23(5):755-766.
69.
Van Damme H. , Demoulin JC, Zicot M., Creemers E., Trotteur G., Limet R.Pathological aspects of carotid plaques. Surgical and clinical significance. J Cardiovasc Surg. 1992;33(1):46-53.
70.
Koh KKEffects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res. 2000 ;47(4): 648-657.
71.
Shah PK, Falk E., Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation . 1995; 92(6):1565-1569.
72.
Aikawa M., Rabkin E., Sugiyama S., et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation. 2001;103(2):276-283.
73.
Libby P., Geng YJ, Aikawa M., et al. Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol. 1996;7(5):330-335.
74.
Galis ZS, Sukhova GK, Lark MW, Libby P.Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94(6):2493-2503.
75.
Crisby M., Nordin-Fredriksson G., Shah PK, Yano J., Zhu J., Nilsson J.Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation . 2001;103(7):926-933.
76.
de Lorenzo F., Feher M., Martin J., Collot-Teixeira S., Dotsenko O., McGregor JLStatin therapy-evidence beyond lipid lowering contributing to plaque stability . Curr Med Chem. 2006;13(28):3385-3393.
77.
Pietsch A., Erl W., Lorenz RLLovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. Biochem Pharmacol . 1996;52(3):433-439.
78.
Fuhrman B., Koren L., Volkova N., Keidar S., Hayek T., Aviram M.Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized LDL by differentiating monocytes. Atherosclerosis . 2002;164(1):179-185.
79.
Hrboticky N. , Draude G., Hapfelmeier G., Lorenz R., Weber PCLovastatin decreases the receptor-mediated degradation of acetylated and oxidized LDLs in human blood monocytes during the early stage of differentiation into macrophages . Arterioscler Thromb Vasc Biol. 1999;19(5):1267-1275.
80.
Amarenco P. , Labreuche J., Lavallee P., Touboul PJStatins in stroke prevention and carotid atherosclerosis: systemic review and up-to-date metaanalysis . Stroke. 2004;35(12):2902-2909.
81.
Salonen R., Seppanen K., Rauramaa R., Salonen JTPrevalence of carotid atherosclerosis and serum cholesterol levels in eastern Finland. Arteriosclerosis. 1988 ;8(6):788-792.
82.
Rubens J., Espeland MA, Ryu J., et al. Individual variation in susceptibility to extracranial carotid atherosclerosis. Arteriosclerosis. 1988;8(4):389-397.
83.
Kang S., Wu Y., Li X.Effects of statin therapy on the progression of carotid atherosclerosis: a systemic review and meta-analysis. Atherosclerosis. 2004;177(2):433-442.
84.
Prospective Studies Collaboration.Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts. Lancet. 1995;346(8991-8992):1647-1653.
85.
Shepherd J. , Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623-1630.
86.
Amarenco P. , Goldstein LB, Szarek M., et al. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack. Stroke. 2007;38(12):3198-3204.
87.
Amarenco P. , Goldstein LB, Callahan A., et al. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis. 2009;204(2):515-520.
88.
Baigent C., Keech A., Kearney KM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-1278.
89.
Collins R., Armitage J., Parish S., et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004 ;363(9411):757-767.
90.
Stalenhoef AFH.The benefit of statins in non-cardiac vascular surgery patients. J Vasc Surg. 2009;49(1):260-165.
91.
National cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). 2002.
92.
Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extermity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interverntions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol . 2006;47:1239-312.
93.
Coppola G., Novo S.Statins and peripheral arterial disease: effects on claudication, disease progression, and prevention of cardiovascular events. Arch Med Res. 2007;38(5):479-488.
94.
Pitsavos CE , Aggeli KI, Barbetseas JD, et al. Effects of pravastatin on thoracic aortic atherosclerosis in patients with heterozygous familial hypercholesterolemia . Am J Cardiol. 1998;82(12): 1484-1488.
95.
Tomochika Y. , Okuda F., Tanaka N., et al. Improvement of atherosclerosis and stiffness of the thoracic descending aorta with cholesterol-lowering therapies in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1996;16(8):955-962.
96.
Kertai MD, Boersma E., Westerhout CM, et al. Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. Am J Med. 2004;116(2): 96-103.
97.
Sukhija R., Aronow WS, Sandhu R., Kakar P., Babu S.Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol. 2006;97(2):279-280.
98.
Schouten O. , van Laanen JHH, Boersma E., et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth . Eur J Vasc Endovasc Surg. 2006;32(1):21-26.
99.
Mosorin M., Niemela E., Heikkinen J., et al. The use of statins and fate of small abdominal aortic aneurysms . Interact Cardiovasc Thorac Surg. 2008;7(4):578-581.
100.
Schlosser FJV , Tangelder MJD, Verhagen HJM, et al. Growth predictors and prognosis of small abdominal aortic aneurysms. J Vasc Surg. 2008;47(6):1127-1133.
101.
Feeney JM, Burns K., Staff I., et al. Prehospital HMG Co-A reductase inhibitor use and reduced mortality in ruptured abdominal aortic aneurysm. J Am Coll Surg. 2009;209(1):41-46.
102.
Golledge J. , Powell JTMedical management of abdominal aortic aneurysm . Eur J Vasc Endovasc Surg. 2007;34(3):267-273.
103.
Evans J., Powell JT, Schwalbe E., Loftus IM, Thompson MMSimvastatin attenuates the activity of matrix metalloprotease-9 in aneurysmal aortic tissue. Eur J Vasc Endovasc Surg. 2007 ; 34(3):302-303.
104.
Norgren L. , Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33(suppl):S1-S75.
105.
Blankenhorn DH, Azen SP, Crawford DW, et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation. 1991;83(2):438-447.
106.
Heart Protection Study Collaborative Group.Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20, 536 people with peripheral arterial disease and other high-risk conditions . J Vasc Surg. 2007;45(4):645-654.
107.
Feringa HHH , Karagiannis SE, van Waning VH, et al. The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease . J Vasc Surg. 2007; 45(5):936-943.
108.
Schanzer A. , Hevelone N., Owens CD, Beckman JA, Belkin M., Conte MSStatins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. J Vasc Surg. 2008 ;47(4): 774-781.
109.
McDermott MM, Guralnik JM, Greenland P., et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation. 2003;107(5):757-761.
110.
Mohler EM III , Hiatt WR , Creager MACholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 2003;108(12):1481-1486.
111.
Mondillo S. , Ballo P., Barbati R., et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med. 2003;114(5):359-364.
112.
Schillinger M., Exner M., Mlekusch W., et al. Statin therapy improves cardiovascular outcome of patients with peripheral arterial disease . Eur Heart J. 2004;25(9):742-748.
113.
Henke PK, Blackburn S., Proctor MC, et al. Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed carioprotective medications: effect on graft patency, limb salvage, and mortality. J Vasc Surg. 2004;39(2): 357-365.
114.
Abbruzzese TA , Havens J., Belkin M., et al. Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts . J Vasc Surg. 2004;39(6):1178-1185.
115.
Ward RP, Leeper NJ, Kirkpatrick JN, Lang RM, Sorrentino MJ, Williams KAThe effect of preoperative statin therapy on cardiovascular outcomes in patients undergoing infrainguinal vascular surgery. Int J Cardiol. 2005;104(3):264-268.
116.
Conte MS, Bandyk DF, Clowes AW, et al. Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial . J Vasc Surg. 2005;42(3):456-465.
117.
Conte MS, Bandyk DF, Clowes AW, et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery . J Vasc Surg. 2006;43(4):742-751.
118.
Blum ASManagement of dyslipidemia with statins in the patient with peripheral arterial disease. Tech Vasc Interv Radiol. 2006;9(2):50-55.
119.
McKenney JMPotential nontraditional applications of statins . Ann Pharmacother. 2003;37(7-8):1063-1071.
120.
Hankey GJ, Norman PEMedical treatment of peripheral arterial disease. JAMA. 2006;295(5):547-553.
121.
Corsini A. , Bellosta S., Baetta R., Fumagalli R., Paoletti R., Bernini F.New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999;84(3):413-428.
122.
Garnett WRInteractions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health Syst Pharm. 1995;52(15): 1639-1645.
123.
Hamelin B. , Turgeon J.Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors . Trends Pharmacol Sci. 1998;19(1):26-37.
124.
Neuvonen PJ , Niemi M., Backman JTDrug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80(6):565-581.
125.
Schachter M.Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19(1):117-125.
Herman RJDrug interactions and the statins. CMAJ. 1999 ; 161(10):1281-1286.
134.
Bertz RJ, Granneman GRUse of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet. 1997;32(3):210-258.
135.
Paoletti R. , Corsini A., Bellosta S.Pharmacological interactions of statins. Atheroscler Suppl. 2002;3(1):35-40.
